Efficacy of early treatment with infliximab in pediatric Crohn’s disease

Table 2 Differences in baseline characteristics of each treatment group

	Group A	Group B	Group C	P
Median age (range, yr)	13 (10-14)	12.5 (4-14)	14 (1-16)	0.520
Duration of follow up (mo) (mean ± SD)	82.7 ± 29.1	50.3 ± 15.5	29.6 ± 7.4	0.234
PCDAI (mean ± SD)	30.3 ± 6.5	33.1 ± 9.9	34.8 ± 8.8	0.464

Group A: Treated with mesalamine after induction therapy with oral prednisolone; Group B: Treated with azathioprine after induction therapy with oral prednisolone; Group C: Treated with infliximab and azathioprine for induction and maintenance therapy.